FOCUS Trial of HEPZATO KIT Shows Efficacy in Metastatic Uveal Melanoma
Source: Targeted Oncology, May 2024
A study found that treatment with HEPZATO KIT showed a promising response rate of 36.3% for patients with unresectable metastatic uveal melanoma.
Treatment with the HEPZATO KIT (melphalan/Hepatic Delivery System) demonstrated a 36.3% (95% CI, 26.4%-47.0%) overall response rate (ORR), including 7.7% of patients with complete response, among those with unresectable metastatic uveal melanoma (mUM), according to results from the pivotal phase 3 FOCUS study.
Findings were recently published in the journal Annals of Surgical Oncology. In addition to promising findings for the primary efficacy end point of ORR as determined by an independent review committee, 37.4% of patients had stable disease (SD). The partial response rate was 28.6%.